Milestone achieved for Global Anti-Epileptic program

We are happy to congratulate first site-participant of epilepsy trial opened in Russia last month under GCT management. It officially launches the enrollment for the Phase III multinational study in patients with drug-resistant partial-onset seizures.

Updated: December 3, 2015

Permanent link: https://2022.gctrials.com/news/milestone-achieved-for-global-anti-epileptic-program/

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

About

GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login

 

GCT

© 2001—2021 Global Clinical Trials, LLC

All rights reserved.